Immorta Bio Presents SenoVax™ Cancer Senolytic Immunotherapy Preclinical Data at American Association of Immunologists Meeting

PR Newswire

May 5, 2025

Immorta Bio was selected to present alongside Pfizer and the University of Pittsburgh at the 2025 American Association of Immunologists Annual Meeting in Honolulu. The company unveiled new data on SenoVax™, its first-in-class senolytic immunotherapy that trains the immune system to target senescent cells—offering a novel approach to treating both cancer and aging.

‍

Read Full Article

Explore More

March 11, 2026

Immorta Bio Presents SenoVax™ Cancer Senolytic Immunotherapy Preclinical Data at American Association of Immunologists Meeting

Never Miss A Headline

Subscribe to Immorta Bio's Newsletter

Explore More

Immorta Bio Demonstrates Dramatic Lifespan Extension in Aging Mouse Models; Research Accepted for Presentation at AAI's IMMUNOLOGY2026

Renowned Filmmaker and Creative Director Dr. Bob Gordon Joins Immorta Bio Strategic Advisory Board

Immorta Bio Appoints Former Ernst & Young Health Sciences Partner Howard Brooks to Strategic Advisory Board

Immorta Bio Presents SenoVax™ Cancer Senolytic Immunotherapy Preclinical Data at American Association of Immunologists Meeting

Never Miss A Headline

Subscribe to Immorta Bio's Newsletter

Explore More

Immorta Bio Demonstrates Dramatic Lifespan Extension in Aging Mouse Models; Research Accepted for Presentation at AAI's IMMUNOLOGY2026

Renowned Filmmaker and Creative Director Dr. Bob Gordon Joins Immorta Bio Strategic Advisory Board

Immorta Bio Appoints Former Ernst & Young Health Sciences Partner Howard Brooks to Strategic Advisory Board

Cookie Settings